Rocket Pharmaceuticals, Inc.
RCKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $171,244 | $186,342 | $165,570 | $125,476 |
| G&A Expenses | $101,961 | $73,317 | $58,773 | $41,772 |
| SG&A Expenses | $101,961 | $73,317 | $58,773 | $41,772 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $273,205 | $259,659 | $224,343 | $167,248 |
| Operating Income | -$273,205 | -$259,659 | -$224,343 | -$167,248 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $14,459 | $14,064 | $2,480 | -$1,821 |
| Pre-Tax Income | -$258,746 | -$245,595 | -$221,863 | -$169,069 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$258,746 | -$245,595 | -$221,863 | -$169,069 |
| % Margin | – | – | – | – |
| EPS | -2.73 | -2.92 | -3.26 | -2.68 |
| % Growth | 6.5% | 10.4% | -21.6% | – |
| EPS Diluted | -2.73 | -2.92 | -3.26 | -2.68 |
| Weighted Avg Shares Out | 94,808 | 84,009 | 68,149 | 63,235 |
| Weighted Avg Shares Out Dil | 94,808 | 84,009 | 68,149 | 63,235 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18,221 | $15,939 | $3,889 | $3,068 |
| Interest Expense | $1,886 | $1,875 | $1,909 | $5,889 |
| Depreciation & Amortization | $9,375 | $7,098 | $6,266 | $5,373 |
| EBITDA | -$247,485 | -$236,622 | -$213,688 | -$157,807 |
| % Margin | – | – | – | – |